Entyvio (vedolizumab) is a brand-name drug that doctors prescribe for moderate to severe ulcerative colitis and Crohn’s disease. It works by blocking signals that cause white blood cells to move into your gut.

Symptoms of ulcerative colitis (UC) and Crohn’s disease result from gut inflammation. The movement of certain white blood cells into your gut (intestines) causes this inflammation.

Entyvio can help block some signals that cause these white blood cells to move into your gut. This action can decrease the inflammation and other symptoms of UC and Crohn’s disease.

Treatment with Entyvio involves two parts. A doctor gives you the first three starting doses during the induction phase, which lasts a total of 6 weeks. During this phase, the doctor gives you the second dose 2 weeks after the first dose. They give you the third dose 4 weeks after the second dose.

Although symptoms may begin to improve right away after the first infusion, it may take the full 6-week period for symptoms to become more manageable.

The maintenance phase follows the induction phase. During the maintenance phase, a doctor gives doses every 8 weeks to keep symptoms manageable.

Disclaimer: Medical News Today has made every effort to make certain that all information is factually correct, comprehensive, and up to date. However, this article should not be used as a substitute for the knowledge and expertise of a licensed healthcare professional. You should always consult your doctor or another healthcare professional before taking any medication. The drug information contained herein is subject to change and is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. The absence of warnings or other information for a given drug does not indicate that the drug or drug combination is safe, effective, or appropriate for all patients or all specific uses.